Focus Partners Advisor Solutions LLC Has $16.78 Million Holdings in Eli Lilly and Company $LLY

Posted by Geri Gentry on Aug 21st, 2026

Eli Lilly and Company logo Focus Partners Advisor Solutions LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 8.2% during the second quarter, HoldingsChannel.com reports. The fund owned 13,987 shares of the company’s stock after selling 1,254 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Eli Lilly and Company were worth $16,777,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of LLY. S&CO Inc. lifted its holdings in shares of Eli Lilly and Company by 3.6% in the second quarter. S&CO Inc. now owns 22,300 shares of the company’s stock worth $26,747,000 after acquiring an additional 781 shares during the last quarter. Helios Capital Management PTE. Ltd. bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $1,919,000. Kelleher Financial Advisors increased its position in Eli Lilly and Company by 187.1% during the 2nd quarter. Kelleher Financial Advisors now owns 2,498 shares of the company’s stock worth $2,996,000 after purchasing an additional 1,628 shares in the last quarter. EJMK Ventures LLC increased its position in Eli Lilly and Company by 16.6% during the 2nd quarter. EJMK Ventures LLC now owns 752 shares of the company’s stock worth $902,000 after purchasing an additional 107 shares in the last quarter. Finally, Bellars Harris Wealth Management LLC bought a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $4,370,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Sanford C. Bernstein raised their target price on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. Jefferies Financial Group increased their price target on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. Weiss Ratings downgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Finally, Rothschild & Co Redburn upped their target price on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.

View Our Latest Stock Report on Eli Lilly and Company

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Obesity portfolio remains the main catalyst. Lilly’s Zepbound sales reportedly increased 46%, while recent coverage indicates its GLP-1 portfolio is outpacing Novo Nordisk’s in the latest quarter. Investors are also watching oral obesity candidates and retatrutide as potential sources of future growth. How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
Positive Sentiment: Pipeline activity continues across several therapeutic areas. Lilly advanced early-stage studies involving LY4178256, eloralintide, lepodisiran and oral candidate LY4065967, while completing a Phase 3 lebrikizumab trial in atopic dermatitis. These updates do not provide immediate revenue, but they reinforce the company’s longer-term growth prospects. Lilly’s Lebrikizumab Trial Completion Signals New Growth Path
Positive Sentiment: Fundamentals remain strong. Lilly’s latest quarterly earnings and revenue substantially exceeded consensus estimates, with revenue rising 47.7% year over year. Analysts continue to cite GLP-1 momentum and a broad pipeline as reasons for a constructive long-term outlook.
Neutral Sentiment: Lehigh Valley construction plans emphasize traffic mitigation. Lilly outlined measures intended to reduce disruption from construction, an operational update that may ease local execution concerns but is unlikely to materially affect near-term earnings. Eli Lilly Lehigh Valley Construction Plans
Negative Sentiment: Valuation and competition are weighing on sentiment. With LLY valued above $1 trillion and trading at a high earnings multiple, investors may be taking profits after its recent rally. Novo Nordisk and potential entrants such as Pfizer are intensifying the race for oral and next-generation obesity treatments, raising future pricing and market-share risks. Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?

Eli Lilly and Company Trading Down 2.6%

LLY opened at $1,246.89 on Friday. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $694.23 and a fifty-two week high of $1,292.65. The company’s 50 day moving average price is $1,177.74 and its two-hundred day moving average price is $1,058.43. The firm has a market capitalization of $1.17 trillion, a price-to-earnings ratio of 41.84, a PEG ratio of 1.51 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter last year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 23.22%.

Insider Buying and Selling

In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company’s stock, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last three months. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.